ASX - By Stock
|
PER |
FDA approves Sareptas Srp901 for the whole population
|
|
itsagas
|
63 |
20K |
6 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
63
|
20K
|
6
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
0 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
9 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
33
|
10K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
4 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
33
|
10K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
3 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
157
|
39K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
12 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
33
|
10K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
12 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
157
|
39K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
1 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
1 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
0 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
33
|
10K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
2 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
33
|
10K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
4 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
47
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
1 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
5 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
33
|
10K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: Deborah Ambrosini appointed as CFO & Company Secretary
|
|
itsagas
|
33 |
10K |
12 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
33
|
10K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
47
|
13K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
4 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
47
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
4 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
47
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
47
|
13K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
9 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
47
|
13K
|
9
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
2
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
3 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
3
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
1 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
1 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
157
|
39K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
157
|
39K
|
2
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
6 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
6
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
2 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
7 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
47
|
13K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
6 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
47
|
13K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
4 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
47
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
2 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
47
|
13K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
DXB - Research & Valuation
|
|
itsagas
|
230 |
110K |
1 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
230
|
110K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
3 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
47
|
13K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
4 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
47
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
3 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
47
|
13K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
2 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
47
|
13K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Will PER follow DXB on a similar journey ?
|
|
itsagas
|
47 |
13K |
1 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Pfizer’s Duchenne muscular dystrophy gene therapy FAILS Ph3
|
|
itsagas
|
5 |
1.8K |
4 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
5
|
1.8K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Pfizer’s Duchenne muscular dystrophy gene therapy FAILS Ph3
|
|
itsagas
|
5 |
1.8K |
7 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
5
|
1.8K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Pfizer’s Duchenne muscular dystrophy gene therapy FAILS Ph3
|
|
itsagas
|
5 |
1.8K |
6 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
5
|
1.8K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Pfizer’s Duchenne muscular dystrophy gene therapy FAILS Ph3
|
|
itsagas
|
5 |
1.8K |
3 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
5
|
1.8K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Pfizer’s Duchenne muscular dystrophy gene therapy FAILS Ph3
|
|
itsagas
|
5 |
1.8K |
4 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
5
|
1.8K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
2 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
157
|
39K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
157
|
39K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
4 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
157
|
39K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
itsagas
|
157 |
39K |
9 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
157
|
39K
|
9
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
2 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
2
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
3 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
3
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
1 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
1
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
itsagas
|
1.2K |
326K |
0 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
1.2K
|
326K
|
0
|
|